Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cystamine SCHEMBL43866 | 0.84 | — | — | |
| Cystamine SCHEMBL3648870 | 0.84 | TSHR (1.00) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL11040994 | 0.84 | — | — | |
| Cystamine SCHEMBL9242006 | 0.84 | TSHR (0.59) | TSHRTHPOMAPTTDP1EHMT2 | |
| SCHEMBL30463832 | 0.83 | — | — | |
| Cystamine SCHEMBL196510 | 0.81 | — | — | |
| Cystamine SCHEMBL1526281 | 0.81 | TSHR (0.91) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL31402311 | 0.81 | TSHR (0.91) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL9193499 | 0.81 | — | — | |
| Cystamine SCHEMBL320311 | 0.81 | MAPT (1.00) | TSHRTHPOMAPTTDP1EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180338928-A1 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE COMPOUNDS | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2018-11-29 | — | — | US | disclosed |
| WO-2001084976-A2 | SELF-NEUTRALIZING PERMANENT WAVE COMPOSITION AND METHOD THEREFOR | SHISEIDO CO., LTD. (JP) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338928-A1 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE COMPOUNDS | FABP1, GLS2, SLC10A1 | TSHR 2930/4885THPO 4439/4885MAPT 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.